Matthew Byerly
Overview
Explore the profile of Matthew Byerly including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
251
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gasteiger N, Norman G, Grainger R, van der Veer S, McGarrigle L, Jones D, et al.
JAMIA Open
. 2025 Jan;
8(1):ooae159.
PMID: 39810923
Objectives: There is no guidance to support the reporting of systematic reviews of mobile health (mhealth) apps (app reviews), so authors attempt to use/modify the Preferred Reporting Items for Systematic...
2.
Gasteiger N, Norman G, Grainger R, Eost-Telling C, Jones D, Ali S, et al.
BMJ Open
. 2024 Jul;
14(7):e083364.
PMID: 38964792
Introduction: Reviews of commercial and publicly available smartphone (mobile) health applications (mHealth app reviews) are being undertaken and published. However, there is variation in the conduct and reporting of mHealth...
3.
Anderson J, Killian M, Fuller A, Hughes J, Byerly M, Lindow J, et al.
Child Psychiatry Hum Dev
. 2021 Mar;
53(3):546-553.
PMID: 33713250
Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire is a brief 15-item self-report measure of quality of life and life satisfaction originally developed for clinical populations (6 to 17 years...
4.
Kowalski E, Chen J, Hazy A, Fritsch L, Gudenschwager-Basso E, Chen M, et al.
J Neuroinflammation
. 2019 Nov;
16(1):210.
PMID: 31711546
Background: The continuum of pro- and anti-inflammatory response elicited by traumatic brain injury (TBI) is suggested to play a key role in the outcome of TBI; however, the underlying mechanisms...
5.
Sajatovic M, Ross R, Legacy S, Byerly M, Kane J, DiBiasi F, et al.
Neuropsychiatr Dis Treat
. 2018 Jun;
14:1475-1492.
PMID: 29922063
Objective: The aim of this study was to provide recommendations on initiating and maintaining long-acting injectable antipsychotics (LAIs) in individuals with schizophrenia/schizoaffective or bipolar disorder. Methods: A 50-question survey comprising...
6.
Sajatovic M, Ross R, Legacy S, Correll C, Kane J, DiBiasi F, et al.
Neuropsychiatr Dis Treat
. 2018 Jun;
14:1463-1474.
PMID: 29922062
Objective: To assess expert consensus on barriers and facilitators for long-acting injectable antipsychotic (LAI) use and provide clinical recommendations on issues where clinical evidence is lacking, including identifying appropriate clinical...
7.
Jha M, Lambert E, Beadles B, Spradling B, Martinez R, Renfro N, et al.
J Clin Psychopharmacol
. 2015 Oct;
35(6):732-3.
PMID: 26479224
No abstract available.
8.
McEvoy J, Byerly M, Hamer R, Dominik R, Swartz M, Rosenheck R, et al.
JAMA
. 2014 May;
311(19):1978-87.
PMID: 24846035
Importance: Long-acting injectable antipsychotics are used to reduce medication nonadherence and relapse in schizophrenia-spectrum disorders. The relative effectiveness of long-acting injectable versions of second-generation and older antipsychotics has not been...
9.
Bannister E, Nakonezny P, Byerly M
Acad Psychiatry
. 2014 Mar;
38(2):198-204.
PMID: 24619912
Objective: To determine the characteristics of curricula for teaching the content of clinical practice guidelines (CPGs) in psychiatric residency and child and adolescent fellowship programs as well as to determine...
10.
Byerly M, Suppes T, Tran Q, Baker R
J Clin Psychopharmacol
. 2007 Nov;
27(6):639-61.
PMID: 18004132
Hyperprolactinemia is increasingly studied as a frequent and potentially important consequence of antipsychotic medication treatment. Some individuals presenting with hyperprolactinemia remain asymptomatic, but others may exhibit a wide range of...